Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

 
Jul 18, 2017
Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex™ Donepezil Transdermal System at Alzheimer’s Association International Conference® 2017
MENLO PARK, Calif., July 18, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced that Parminder “Bobby” Singh, Ph.D., Corium’s Chief Technology Officer and Vice President, Research …


July 06, 2017
Corium to Present Clinical Results from Pilot Bioequivalence Study of Once-weekly Corplex™ Donepezil Transdermal System at Alzheimer’s Association International Conference® 2017
MENLO PARK, Calif., July 06, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercializa…

OUR LEAD PRODUCT

CorplexTM Donepezil

A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

circle_couple2